



Dkt. 1784/53661-AA/JPW/AJM/MML

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Stewart Shuman et al.

Serial No. : 10/666,486

Filed : September 19, 2003

For : TOPOISOMERASE-BASED REAGENTS AND METHODS FOR  
MOLECULAR CLONING

1185 Avenue of the Americas  
New York, NY 10036  
December 23, 2003

Commissioner for Patents  
P.O. Box 1450  
Alexandria VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants request that the following disclosures be made of record in the above-identified application pursuant to 37 C.F.R. §1.97(b). These references are also listed on the Form PTO-1449 attached hereto as **Exhibit A**. Copies of items 1, 2 and 13 are attached hereto as **Exhibits 1-3**, respectively. The remaining items were previously submitted in connection with prior application U.S. Serial No. 09/096,927.

1. U.S. Patent No. 6,653,106, Shuman et al., issued November 25, 2003 (**Exhibit 1**);
2. U.S. Patent No. 6,548,277, Shuman et al., issued April 15, 2003 (**Exhibit 2**);
3. U.S. Patent No. 6,238,884, Short et al., issued May 29, 2001;

Applicant : Stewart Shuman et al.  
Serial No. : 10/666,486  
Filed : September 19, 2003  
Page 2

4. U.S. Patent No. 6,280,977, Liang et al., issued August 28, 2001;
5. U.S. Patent No. 6,291,213, Rothstein et al., issued September 18, 2001;
6. U.S. Patent No. 5,746,997, Reed M.W., issued May 5, 1998;
7. U.S. Patent No. 5,766,891, Shuman et al., issued June 16, 1998;
8. U.S. Patent No. 5,624,826, Kato et al., issued April 29, 1997;
9. U.S. Patent No. 4,800,159, Mullis et al., issued January 24, 1989;
10. U.S. Patent No. 4,661,450, Kempe et al., issued April 28, 1987;
11. PCT International Application No. PCT/US01/26294, Publication No. WO 02/16594, published February 28, 2002;
12. PCT International Application No. PCT/US01/05657, Publication No. WO 01/62892, published August 30, 2001;
13. PCT International Application No. PCT/US01/05745, Publication No. WO 01/62943, published August 30, 2001  
**(Exhibit 3);**
14. PCT International Application No. PCT/US99/19413, Publication No. WO 00/12687, published March 9, 2000;
15. PCT International Application No. PCT/US00/06560, Publication No. WO 00/56878, published September 28, 2000;

Applicant : Stewart Shuman et al.  
Serial No. : 10/666,486  
Filed : September 19, 2003  
Page 3

16. PCT International Application No. PCT/JP97/03992,  
Publication No. WO 98/20122, published May 14, 1998;
17. PCT International Application No. PCT/US98/11671,  
Publication No. WO 98/55502, published December 10, 1998;
18. PCT International Application No. PCT/US98/12372,  
Publication No. WO 98/56943, published December 17, 1998;
19. PCT International Application No. PCT/US97/00368,  
Publication No. WO 97/24455, published July 10, 1997;
20. PCT International Application No. PCT/US95/16099,  
Publication No. WO 96/19497, published June 27, 1996;
21. PCT International Application No. PCT/FR96/00651,  
Publication No. WO 96/34981, published November 7, 1996;
22. PCT International Application No. PCT/EP94/01869,  
Publication No. WO 94/29443, published December 22, 1994;
23. PCT International Application No. PCT/AU85/00093,  
Publication No. WO 85/04898, published November 7, 1985;
24. European Application No. 89313030.2, Publication No. EP 0  
373 914 B1, published July 13, 1994;
25. European Application No. 93921061.3, Publication No. EP 0  
625 572 B1, published April 18, 2001;
26. Arnott et al. "DNA-RNA hybrid secondary structures," J.  
Mol. Biol. 188(4):631-640 (1986);
27. Carninci et al. "High efficiency selection of full-length  
cDNA by improved biotinylated cap trapper," DNA Research  
4:61-66 (1997);

Applicant : Stewart Shuman et al.  
Serial No. : 10/666,486  
Filed : September 19, 2003  
Page 4

28. Carninci et al. "High-efficiency full-length cDNA cloning by biotinylated CAP trapper," *Genomics* 37(3):327-36 (1996);
29. Cheng and Shuman, "A catalytic domain of eukaryotic DNA topoisomerase I," *J. Biol. Chem.* 273(19):11589-95 (1998);
30. Cheng and Shuman, "DNA strand transfer catalyzed by vaccinia topoisomerase: ligation of DNAs containing a 3' mononucleotide overhang," *Nucleic Acids Res.* 28(9):1893-8 (2000);
31. Cheng and Shuman, "Recombinogenic flap ligation pathway for intrinsic repair of topoisomerase IB-induced double-strand breaks," *Mol. Cell. Biol.* 20(21):8059-8068 (2000);
32. Cheng and Shuman, "Site-specific DNA transesterification by vaccinia topoisomerase: Role of specific phosphates and nucleosides," *Biochemistry* 38(50):16599-612 (1999);
33. Cheng et al. "Conservation of structure and mechanism between eukaryotic topoisomerase I and site-specific recombinases," *Cell* 92(6):841-50 (1998);
34. Cheng et al. "Mutational analysis of 39 residues of vaccinia DNA topoisomerase identifies Lys-220, Arg-223, and Asn-228 as important for covalent catalysis," *J. Biol. Chem.* 272(13):8263-9 (1997);
35. Chong S. et al. "Single-column purification of free recombinant proteins using a self-cleavable affinity tag derived from a protein splicing element," *Gene* 192(2):271-281 (1997);

Applicant : Stewart Shuman et al.  
Serial No. : 10/666,486  
Filed : September 19, 2003  
Page 5

36. DiGate and Marians, "Molecular cloning and DNA sequence analysis of *Escherichia coli* topoB, the gene encoding topoisomerase III," J. Biol. Chem. 264(30):17924-17930 (1989);
37. Edery et al. "An efficient strategy to isolate full-length cDNAs based on an mRNA cap retention procedure (CAPture)," Mol. Cell. Biol. 15(6):3363-3371 (1995);
38. Ericsson et al. "Characterization of ts16, a temperature-sensitive mutant of vaccinia virus," J. Virol. 69(11):7072-86 (1995);
39. Gross and Shuman, "Vaccinia virions lacking the RNA helicase nucleoside triphosphate phosphohydrolase II are defective in early transcription," J. Virol. 70(12):8549-5 (1996);
40. Haghighat and Sonenberg, "eIF4G dramatically enhances the binding of eIF4E to the mRNA 5'-cap structure," J. Biol. Chem. 272(35):21677-21680 (1997);
41. Haghighat et al. "The eIF4G-eIF4E complex is the target for direct cleavage by the rhinovirus 2A proteinase," J. Virol. 70:8444-8450 (1996);
42. Henningfeld and Hecht, "A model for topoisomerase I-mediated insertions and deletions with duplex DNA substrates containing branches, nicks, and gaps," Biochemistry 34(18):6120-9 (1995);
43. Invitrogen Corporation, Carlsbad, California, catalog pages 18, 29, 43, 44, 49-52 (1998);

Applicant : Stewart Shuman et al.  
Serial No. : 10/666,486  
Filed : September 19, 2003  
Page 6

44. Janknecht et al. "Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus," Proc. Natl. Acad. Sci. U.S.A. 88:8972-8976(1991);
45. Kane and Shuman, "Vaccinia virus morphogenesis is blocked by a temperature-sensitive mutation in the I7 gene that encodes a virion component," J. Virol. 67(5):2689-98 (1993);
46. Kato et al. "Construction of a human full-length cDNA bank," Gene 150:243-250 (1994);
47. Klemm et al. "Peptide inhibitors of DNA cleavage by tyrosine recombinases and topoisomerases," J. Mol. Biol. 299(5):1203-16 (2000);
48. Klemperer et al. "Identification and characterization of the orf virus type I topoisomerase," Virology 206:203-215 (1995);
49. Krogh and Shuman, "Catalytic mechanism of DNA topoisomerase IB," Mol. Cell 5(6):1035-41 (2000);
50. Krogh and Shuman, "DNA strand transfer catalyzed by vaccinia topoisomerase: peroxidolysis and hydroxylaminolysis of the covalent protein-DNA intermediate," Biochemistry 39(21):6422-32 (2000);
51. Krogh and Shuman, "Vaccinia topoisomerase mutants illuminate conformational changes during closure of the protein clamp and assembly of a functional active site," J. Biol. Chem. (2001);

Applicant : Stewart Shuman et al.  
Serial No. : 10/666,486  
Filed : September 19, 2003  
Page 7

52. Krogh et al. "Effect of 2'-5' phosphodiesterases on DNA transesterification by vaccinia topoisomerase," J. Biol. Chem. 276(24):20907-20912 (2001);
53. Krogh et al. "Melanoplus sanguinipes entomopoxvirus DNA topoisomerase: site-specific DNA transesterification and effects of 5'-bridging phosphorothiolates," Virology 264(2):441-51 (1999);
54. Liu et al. "Mapping the 5' and 3' ends of tetrahymena thermophila mRNAs using ligase mediated amplification of cDNA ends (RLM-RACE)," Nucleic Acids Res. 21(21):4954-4960 (1993);
55. Lockard et al. "Labeling of eukaryotic messenger RNA 5' terminus with phosphorus-32: Use of tobacco acid pyrophosphatase for removal of cap structure," Gene Amp. Anal. 2:229-251 (1981);
56. Maruyama et al. "Oligo-Capping: A simple method to replace the cap structure of eukaryotic mRNAs with oligonucleotides," Gene 138:171-174 (1994);
57. Matthews et al. "Analytical strategies for the use of DNA probes," Anal. Biochem. 169:1-25 (1988);
58. Morham and Shuman, "Covalent and noncovalent DNA binding by mutants of vaccinia DNA topoisomerase I," J. Biol. Chem. 267:15984-15992 (1992);
59. Morham and Shuman, "Phenotypic selection and characterization of mutant alleles of a eukaryotic DNA topoisomerase I," Genes. Dev. 4(4):515-24 (1990);

Applicant : Stewart Shuman et al.  
Serial No. : 10/666,486  
Filed : September 19, 2003  
Page 8

60. Palaniyar et al. "SFV topoisomerase: sequence specificity in a genetically mapped interval," *Virology* 221:351-354 (1996);
61. Petersen and Shuman, "DNA strand transfer reactions catalyzed by vaccinia topoisomerase: hydrolysis and glycerololysis of the covalent protein-DNA intermediate," *Nucleic Acids Res.* 25(11):2091-7 (1997);
62. Petersen and Shuman, "Histidine 265 is important for covalent catalysis by vaccinia topoisomerase and is conserved in all eukaryotic type I enzymes," *J. Biol. Chem.* 272(7):3891-6 (1997);
63. Petersen et al. "Characterization of a DNA topoisomerase encoded by *Amsacta moore* entomopoxvirus," *Virology* 230(2):197-206 (1997);
64. Petersen et al. "Mutations within a conserved region of vaccinia topoisomerase affect the DNA cleavage-religation equilibrium," *J. Mol. Biol.* 1263(2):181-95 (1996);
65. Salazar et al. "The DNA strand in DNA:RNA hybrid duplexes is neither B-form nor A-form in solution," *Biochemistry* 32(16):4207-15 (1993);
66. Schmitt et al. "Affinity purification of histidine-tagged proteins," *Mol. Biol. Reports* 18:223-230 (1993);
67. Sekiguchi and Shuman, "Covalent DNA binding by vaccinia topoisomerase results in unpairing of the thymine base 5' of the scissile bond," *J. Biol. Chem.* 271(32):19436-42 (1996);



Applicant : Stewart Shuman et al.  
Serial No. : 10/666,486  
Filed : September 19, 2003  
Page 9

68. Sekiguchi and Shuman, "Domain structure of vaccinia DNA ligase," *Nucleic Acids Res.* 25(4):727-34 (1997);
69. Sekiguchi and Shuman, "Identification of contacts between topoisomerase I and its target DNA by site-specific photocrosslinking," *EMBO J.* 15(13):3448-57 (1996);
70. Sekiguchi and Shuman, "Mutational analysis of vaccinia virus topoisomerase identifies residues involved in DNA binding," *Nucleic Acids Res.* 25(18):3649-56 (1997);
71. Sekiguchi and Shuman, "Nick sensing by vaccinia virus DNA ligase requires a 5' phosphate at the nick and occupancy of the adenylate binding site on the enzyme," *J. Virol.* 71(12):9679-84 (1997);
72. Sekiguchi and Shuman, "Proteolytic footprinting of vaccinia topoisomerase bound to DNA," *J. Biol. Chem.* 270(19):11636-45 (1995);
73. Sekiguchi and Shuman, "Requirements for noncovalent binding of vaccinia topoisomerase I to duplex DNA," *Nucleic Acids Res.* 22(24):5360-5 (1994);
74. Sekiguchi and Shuman, "Site-specific ribonuclease activity of eukaryotic DNA topoisomerase I," *Mol. Cell* 1(1):89-97. (1997);
75. Sekiguchi and Shuman, "Stimulation of vaccinia topoisomerase I by nucleoside triphosphates," *J. Biol. Chem.* 269(47):29760-4 (1994);

Applicant : Stewart Shuman et al.  
Serial No. : 10/666,486  
Filed : September 19, 2003  
Page 10

76. Sekiguchi and Shuman, "Vaccinia topoisomerase binds circumferentially to DNA," J. Biol. Chem. 269(50):31731-4 (1994);
77. Sekiguchi et al. "Kinetic analysis of DNA and RNA strand transfer reactions catalyzed by vaccinia topoisomerase," J. Biol. Chem. 272(25):15721-15728 (1997);
78. Sekiguchi et al. "Mechanism of inhibition of vaccinia DNA topoisomerase by novobiocin and coumermycin," J. Biol. Chem. 271(4):2313-22 (1996);
79. Sekiguchi et al. "Resolution of a Holliday junction by vaccinia topoisomerase requires a spacer DNA segment 3' of the CCCTT/ cleavage sites," Nucleic Acids Res. 28(14):2658-63 (2000);
80. Sekiguchi et al. "Resolution of Holliday junctions by eukaryotic DNA topoisomerase I," Proc. Natl. Acad. Sci. U.S.A. 93(2):785-9 (1996);
81. Shatkin, "Capping of eukaryotic mRNAs," Cell 9(4):645-653 (1976);
82. Shuman and Moss, "Identification of a vaccinia virus gene encoding a type I DNA topoisomerase," Proc. Natl. Acad. Sci. U.S.A. 84:7478-7482 (1987);
83. Shuman and Prescott, "Specific DNA cleavage and binding of vaccinia virus DNA topoisomerase I," J. Biol. Chem. 265:17826-17836 (1990);

Applicant : Stewart Shuman et al.  
Serial No. : 10/666,486  
Filed : September 19, 2003  
Page 11

84. Shuman and Turner, "Site-specific interaction of vaccinia virus topoisomerase I with base and sugar moieties in duplex DNA," J. Biol. Chem. 268(25):18943-50 (1993);
85. Shuman et al. "Characterization of vaccinia virus DNA topoisomerase I expressed in Escherichia coli," J. Biol. Chem. 263:16401-16407 (1988);
86. Shuman et al. "Insertional mutagenesis of the vaccinia virus gene encoding a type I DNA topoisomerase: evidence that the gene is essential for virus growth," Virology 170(1):302-6 (1989);
87. Shuman et al. "Intramolecular synapsis of duplex DNA by vaccinia topoisomerase," EMBO J. 16(21):6584-9 (1997);
88. Shuman et al. "Mapping the active-site tyrosine of vaccinia virus DNA topoisomerase I," Proc. Natl. Acad. Sci. U.S.A. 86(24):9793-7 (1989);
89. Shuman, "Analysis of topoisomerase-DNA interactions by electrophoretic mobility shift assay," Methods Mol. Biol. 95:65-74(2001);
90. Shuman, "DNA strand transfer reactions catalyzed by vaccinia topoisomerase I," J. Biol. Chem. 267:8620-8627 (1992);
91. Shuman, "Novel approach to molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase," J. Biol. Chem. 269(51):32678-32684 (1994);

Applicant : Stewart Shuman et al.  
Serial No. : 10/666,486  
Filed : September 19, 2003  
Page 12

92. Shuman, "Polynucleotide ligase activity of eukaryotic topoisomerase I," *Mol. Cell.* 1(5):741-8 (1998);
93. Shuman, "Recombination mediated by vaccinia virus DNA topoisomerase I in *Escherichia coli* is sequence specific," *Proc. Natl. Acad. Sci. U.S.A.* 88(22):10104-8 (1991);
94. Shuman, "Site-specific DNA cleavage by vaccinia virus DNA topoisomerase I. Role of nucleotide sequence and DNA secondary structure," *J. Biol. Chem.* 266(3):1796-1803 (1991);
95. Shuman, "Site-specific interaction of vaccinia virus topoisomerase I with duplex DNA. Minimal DNA substrate for strand cleavage in vitro," *J. Biol. Chem.* 266(17):11372-11379 (1991);
96. Shuman, "Two classes of DNA end-joining reactions catalyzed by vaccinia topoisomerase I," *J. Biol. Chem.* 267:16755-16758 (1992);
97. Shuman, "Vaccinia DNA topoisomerase I promotes illegitimate recombination in *Escherichia coli*," *Proc. Natl. Acad. Sci. U.S.A.* 86(10):3489-93 (1989);
98. Shuman, "Vaccinia virus DNA ligase: specificity, fidelity, and inhibition," *Biochemistry* 34:16138-16147 (1995);
99. Shuman, "Vaccinia virus DNA topoisomerase: a model eukaryotic type IB enzyme," *Biochim. Biophys. Acta.* 1400(1-3):321-37 (1998);

Applicant : Stewart Shuman et al.  
Serial No. : 10/666,486  
Filed : September 19, 2003  
Page 13

100. Stivers et al. "Stereochemical outcome and kinetic effects of Rp- and Sp-phosphorothioate substitutions at the cleavage site of vaccinia type I DNA topoisomerase," *Biochemistry* 39(18):5561-72 (2000);
101. Stivers et al. "Vaccinia DNA topoisomerase I: single-turnover and steady-state kinetic analysis of the DNA strand cleavage and ligation reactions," *Biochemistry* 33(1):327-39 (1994);
102. Theus, "A simple assay for determining the capping efficiencies of RNA polymerases used for in vitro transcription," *Biotechniques* 9(5):610-615 (1990);
103. Wang and Shuman, "Deletions at the carboxyl terminus of vaccinia DNA topoisomerase affect DNA binding and enhance distributivity in DNA relaxation," *Biochemistry* 36(13):3909-16 (1997);
104. Wang et al. "Mutational analysis of 26 residues of vaccinia DNA topoisomerase identifies Ser-204 as important for DNA binding and cleavage," *Biochemistry* 36(26):7944-50 (1997);
105. Wexler et al. "A procedure to amplify cDNA from dsRNA templates using the Polymerase chain reaction," *Methods Mol. Cell. Biol.* 2:273-279 (1991);
106. Wittschieben and Shuman, "Mechanism of DNA transesterification by vaccinia topoisomerase: catalytic contributions of essential residues Arg-130, Gly-132, Tyr-136 and Lys-167," *Nucleic Acids Res.* 25(15):3001-8 (1997);

Applicant : Stewart Shuman et al.  
Serial No. : 10/666,486  
Filed : September 19, 2003  
Page 14


107. Wittschieben and Shuman, "Mutational analysis of vaccinia DNA topoisomerase defines amino acid residues essential for covalent catalysis," J. Biol. Chem. 269(47):29978-83 (1994);
108. Wittschieben et al. "Replacement of the active site tyrosine of vaccinia DNA topoisomerase by glutamate, cysteine or histidine converts the enzyme into a site-specific endonuclease," Nucleic Acids Res. 26(2):490-6 (1998);
109. Woodfield et al. "Vaccinia topoisomerase and Cre recombinase catalyze direct ligation of activated DNA substrates containing a 3'-para-nitrophenyl phosphate ester," Nucleic Acids Res. 28(17):3323-31 (2000); and
110. Yang et al. "A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases," Proc. Natl. Acad. Sci. U.S.A. 93(21):11534-9 (1996).

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Applicant : Stewart Shuman et al.  
Serial No. : 10/666,486  
Filed : September 19, 2003  
Page 15


If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorneys invite the Examiner to telephone them at the number provided below.

Respectfully submitted,

  
John P. White  
Registration No. 28,678  
Alan J. Morrison  
Registration No. 37,399  
Attorneys for Applicants  
Cooper & Dunham, LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria VA 22313-1450

  
Alan J. Morrison  
Reg. No. 37,399

12/23/03

Date

<b>Form PTO-1449</b>		<b>U.S. Department of Commerce Patent and Trademark Office</b>			<b>Atty. Docket No.</b> 53661-AA/JPW/AJM/MML		<b>Serial No.</b> 10/666,486							
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)					<b>Applicants</b> Stewart Shuman et al.									
					<b>Filing Date</b> September 19, 2003		<b>Group</b>							
<b>U.S. PATENT DOCUMENTS</b>														
<b>Examiner Initial</b>		<b>Document Number</b>						<b>Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	<b>Filing Date if Appropriate</b>		
		6	6	5	3	1	0	6	11/25/2003	Shuman et al.	435	91.1		
		6	5	4	8	2	7	7	4/15/03	Shuman et al.	435	91.4		
		6	2	3	8	8	8	4	5/29/01	Short et al.	435	69.1		
		6	2	8	0	9	7	7	8/28/01	Liang et al.	435	91.2		
		6	2	9	1	2	1	3	9/18/01	Rothstein et al.	435	91.2		
<b>FOREIGN PATENT DOCUMENTS</b>														
		<b>Document Number</b>						<b>Date</b>	<b>Country</b>	<b>Class</b>	<b>Subclass</b>	<b>Translation</b>		
													<b>Yes</b>	<b>No</b>
	WO	0	2	1	6	5	9	4	2/28/02	PCT				
	WO	0	1	6	2	8	9	2	8/30/01	PCT				
	WO	0	1	6	2	9	4	3	8/30/01	PCT				
	WO	0	0	1	2	6	8	7	3/9/00	PCT	C12N	15/00		
	WO	0	0	5	6	8	7	8	9/28/00	PCT	C12N	15/10		
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
		Arnott et al. "DNA-RNA hybrid secondary structures," J. Mol. Biol. 188(4):631-640 (1986);												
		Carninci et al. "High efficiency selection of full-length cDNA by improved biotinylated cap trapper," DNA Research 4:61-66 (1997);												
		Carninci et al. "High-efficiency full-length cDNA cloning by biotinylated CAP trapper," Genomics 37(3):327-36 (1996);												
		Cheng and Shuman, "A catalytic domain of eukaryotic DNA topoisomerase I," J. Biol. Chem. 273(19):115898-95 (1998);												
		Cheng and Shuman, "DNA strand transfer catalyzed by vaccinia topoisomerase: ligation of DNAs containing a 3' mononucleotide overhang," Nucleic Acids Res. 28(9):1893-8 (2000);												
		Cheng and Shuman, "Recombinogenic flap ligation pathway for intrinsic repair of topoisomerase IB-induced double-strand breaks," Mol. Cell. Biol. 20(21):8059-8068 (2000);												
<b>EXAMINER</b>						<b>DATE CONSIDERED</b>								
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.														



<b>Form PTO-1449</b>		<b>U.S. Department of Commerce Patent and Trademark Office</b>			<b>Atty. Docket No.</b> 53661-AA/JPW/AJM/MML		<b>Serial No.</b> 10/666,486							
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)					<b>Applicants</b> Stewart Shuman et al.									
					<b>Filing Date</b> September 19, 2003		<b>Group</b>							
<b>U.S. PATENT DOCUMENTS</b>														
<b>Examiner Initial</b>		<b>Document Number</b>						<b>Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	<b>Filing Date if Appropriate</b>		
		5	7	4	6	9	9	7	5/5/98	Reed, M.W.				
		5	7	6	6	8	9	1	6/16/98	Shuman et al.				
		5	6	2	4	8	2	6	4/29/97	Kato et al.	435	91.4	06/06/95	
		4	8	0	0	1	5	9	1/24/89	Mullis et al.	435	172.3	12/17/86	
		4	6	6	1	4	5	0	4/28/87	Kempe et al.	435	172.3	05/03/83	
<b>FOREIGN PATENT DOCUMENTS</b>														
		<b>Document Number</b>						<b>Date</b>	<b>Country</b>	<b>Class</b>	<b>Subclass</b>	<b>Translation</b>		
													<b>Yes</b>	<b>No</b>
	WO	9	8	2	0	1	2	2	5/14/98	PCT	C12N	15/10		
	WO	9	8	5	5	5	0	2	12/10/98	PCT	C07K	5/00		
	WO	9	8	5	6	9	4	3	12/17/98	PCT	C12P	19/34		
	WO	9	7	2	4	4	5	5	7/10/97	PCT				
	WO	9	6	1	9	4	9	7	6/27/96	PCT	C07K	14/07		
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
		Cheng and Shuman, "Site-specific DNA transesterification by vaccinia topoisomerase: Role of specific phosphates and nucleosides," Biochemistry 38(50):16599-612 (1999);												
		Cheng et al. "Conservation of structure and mechanism between eukaryotic topoisomerase I and site-specific recombinases," Cell 92(6):841-50 (1998);												
		Cheng et al. "Mutational analysis of 39 residues of vaccinia DNA topoisomerase identifies Lys-220, Arg-223, and Asn-228 as important for covalent catalysis," J. Biol. Chem. 272(13):8263-9 (1997);												
		Chong S. et al. "Single-column purification of free recombinant proteins using a self-cleavable affinity tag derived from a protein splicing element," Gene 192(2):271-281 (1997);												
		DiGate and Marians, "Molecular cloning and DNA sequence analysis of Escherichia coli topoB, the gene encoding topoisomerase III," J. Biol. Chem. 264(30):17924-17930 (1989);												
		Edery et al. "An efficient strategy to isolate full-length cDNAs based on an mRNA cap retention procedure (CAPture)," Mol. Cell. Biol. 15(6):3363-3371 (1995);												
<b>EXAMINER</b>					<b>DATE CONSIDERED</b>									
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.														

<b>Form PTO-1449</b>		<b>U.S. Department of Commerce Patent and Trademark Office</b>			<b>Atty. Docket No.</b> 53661-AA/JPW/AJM/MML		<b>Serial No.</b> 10/666,486								
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)					<b>Applicants</b> Stewart Shuman et al.										
					<b>Filing Date</b> September 19, 2003		<b>Group</b>								
<b>U.S. PATENT DOCUMENTS</b>															
<b>Examiner Initial</b>		<b>Document Number</b>							<b>Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	<b>Filing Date if Appropriate</b>		
<b>FOREIGN PATENT DOCUMENTS</b>															
		<b>Document Number</b>							<b>Date</b>	<b>Country</b>	<b>Class</b>	<b>Subclass</b>	<b>Translation</b>		
														<b>Yes</b>	<b>No</b>
	WO	9	6	3	4	9	8	1	11/7/96	PCT	C12Q	1/68			
	WO	9	4	2	9	4	4	3	12/22/94	PCT	C12N	15/10			
	WO	8	5	0	4	8	9	8	11/7/85	PCT	C12N	15/00			
	EP	0	3	7	3	9	1	4	4/13/94	EPO	C12N	15/10			
	EP	0	6	2	5	5	7	2	4/18/01	EPO	C12N	15/10			
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>															
		Ericsson et al. "Characterization of ts16, a temperature-sensitive mutant of vaccinia virus," J. Virol. 69(11):7072-86 (1995);													
		Gross and Shuman, "Vaccinia virions lacking the RNA helicase nucleoside triphosphate phosphohydrolase II are defective in early transcription," J. Virol. 70(12):8549-5 (1996);													
		Haghighat and Sonenberg, "eIF4G dramatically enhances the binding of eIF4E to the mRNA 5'-cap structure," J. Biol. Chem. 272(35):21677-21680 (1997);													
		Haghighat et al. "The eIF4G-eIF4E complex is the target for direct cleavage by the rhinovirus 2A proteinase," J. Virol. 70:8444-8450 (1996);													
		Henningfeld and Hecht, "A model for topoisomerase I-mediated insertions and deletions with duplex DNA substrates containing branches, nicks, and gaps," Biochemistry 34(18):6120-9 (1995);													
		Invitrogen Corporation, Carlsbad, California, catalog pages 18, 29, 43, 44, 49-52 (1998);													
<b>EXAMINER</b>									<b>DATE CONSIDERED</b>						
<b>*EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.															

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 53661-AA/JPW/AJM/MML	Serial No. 10/666,486
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicants Stewart Shuman et al.	
		Filing Date September 19, 2003	Group
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	Janknecht et al. "Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus," Proc. Natl. Acad. Sci. U.S.A. 88:8972-8976(1991);		
	Kane and Shuman, "Vaccinia virus morphogenesis is blocked by a temperature-sensitive mutation in the I7 gene that encodes a virion component," J. Virol. 67(5):2689-98 (1993);		
	Kato et al. "Construction of a human full-length cDNA bank," Gene 150:243-250 (1994);		
	Klemm et al. "Peptide inhibitors of DNA cleavage by tyrosine recombinases and topoisomerases," J. Mol. Biol. 299(5):1203-16 (2000);		
	Klemperer et al. "Identification and characterization of the orf virus type I topoisomerase," Virology 206:203-215 (1995);		
	Krogh and Shuman, "Catalytic mechanism of DNA topoisomerase IB," Mol. Cell 5(6):1035-41 (2000);		
	Krogh and Shuman, "DNA strand transfer catalyzed by vaccinia topoisomerase: peroxidolysis and hydroxylaminolysis of the covalent protein-DNA intermediate," Biochemistry 39(21):6422-32 (2000);		
	Krogh and Shuman, "Vaccinia topoisomerase mutants illuminate conformational changes during closure of the protein clamp and assembly of a functional active site," J. Biol. Chem. 276:36091-99 (2001);		
	Krogh et al. "Effect of 2'-5' phosphodiesterases on DNA transesterification by vaccinia topoisomerase," J. Biol. Chem. 276(24):20907-20912 (2001);		
	Krogh et al. "Melanoplus sanguinipes entomopoxvirus DNA topoisomerase: site-specific DNA transesterification and effects of 5'-bridging phosphorothiolates," Virology 264(2):441-51 (1999);		
	Liu et al. "Mapping the 5' and 3' ends of tetrahymena thermophila mRNAs using ligase mediated amplification of cDNA ends (RLM-RACE)," Nucleic Acids Res. 21(21):4954-4960 (1993);		
	Lockard et al. "Labeling of eukaryotic messenger RNA 5' terminus with phosphorus-32: Use of tobacco acid pyrophosphatase for removal of cap structure," Gene Amp. Anal. 2:229-251 (1981);		
	Maruyama et al. "Oligo-Capping: A simple method to replace the cap structure of eukaryotic mRNAs with oligonucleotides," Gene 138:171-174 (1994);		
EXAMINER		DATE CONSIDERED	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.			

<b>Form PTO-1449</b>	<b>U.S. Department of Commerce Patent and Trademark Office</b>		<b>Atty. Docket No.</b> 53661-AA/JPW/AJM/MML	<b>Serial No.</b> 10/666,486		
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		<b>Applicants</b> Stewart Shuman et al.				
		<b>Filing Date</b> September 19, 2003	<b>Group</b>			
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>						
Matthews et al. "Analytical strategies for the use of DNA probes," Anal. Biochem. 169:1-25 (1988);						
Morham and Shuman, "Covalent and noncovalent DNA binding by mutants of vaccinia DNA topoisomerase I," J. Biol. Chem. 267:15984-15992 (1992);						
Morham and Shuman, "Phenotypic selection and characterization of mutant alleles of a eukaryotic DNA topoisomerase I," Genes. Dev. 4(4):515-24 (1990);						
Palaniyar et al. "SFV topoisomerase: sequence specificity in a genetically mapped interval," Virology 221:351-354 (1996);						
Petersen and Shuman, "DNA strand transfer reactions catalyzed by vaccinia topoisomerase: hydrolysis and glycerololysis of the covalent protein-DNA intermediate," Nucleic Acids Res. 25(11):2091-7 (1997);						
Petersen and Shuman, "Histidine 265 is important for covalent catalysis by vaccinia topoisomerase and is conserved in all eukaryotic type I enzymes," J. Biol. Chem. 272(7):3891-6 (1997);						
Petersen et al. "Characterization of a DNA topoisomerase encoded by Amsacta moore entomopoxvirus," Virology 230(2):197-206 (1997);						
Petersen et al. "Mutations within a conserved region of vaccinia topoisomerase affect the DNA cleavage-religation equilibrium," J. Mol. Biol. 1263(2):181-95 (1996);						
Salazar et al. "The DNA strand in DNA:RNA hybrid duplexes is neither B-form nor A-form in solution," Biochemistry 32(16):4207-15 (1993);						
Schmitt et al. "Affinity purification of histidine-tagged proteins," Mol. Biol. Reports 18:223-230 (1993);						
Sekiguchi and Shuman, "Covalent DNA binding by vaccinia topoisomerase results in unpairing of the thymine base 5' of the scissile bond," J. Biol. Chem. 271(32):19436-42 (1996);						
Sekiguchi and Shuman, "Domain structure of vaccinia DNA ligase," Nucleic Acids Res. 25(4):727-34 (1997);						
Sekiguchi and Shuman, "Identification of contacts between topoisomerase I and its target DNA by site-specific photocrosslinking," EMBO J. 15(13):3448-57 (1996);						
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.						

<b>Form PTO-1449</b>	<b>U.S. Department of Commerce Patent and Trademark Office</b>		<b>Atty. Docket No.</b> 53661-AA/JPW/AJM/MML	<b>Serial No.</b> 10/666,486
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		<b>Applicants</b> Stewart Shuman et al.		
		<b>Filing Date</b> September 19, 2003	<b>Group</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>				
	Sekiguchi and Shuman, "Mutational analysis of vaccinia virus topoisomerase identifies residues involved in DNA binding," Nucleic Acids Res. 25(18):3649-56 (1997);			
	Sekiguchi and Shuman, "Nick sensing by vaccinia virus DNA ligase requires a 5' phosphate at the nick and occupancy of the adenylate binding site on the enzyme," J. Virol. 71(12):9679-84 (1997);			
	Sekiguchi and Shuman, "Proteolytic footprinting of vaccinia topoisomerase bound to DNA," J. Biol. Chem. 270(19):11636-45 (1995);			
	Sekiguchi and Shuman, "Requirements for noncovalent binding of vaccinia topoisomerase I to duplex DNA," Nucleic Acids Res. 22(24):5360-5 (1994);			
	Sekiguchi and Shuman, "Site-specific ribonuclease activity of eukaryotic DNA topoisomerase I," Mol. Cell 1(1):89-97.(1997);			
	Sekiguchi and Shuman, "Stimulation of vaccinia topoisomerase I by nucleoside triphosphates," J. Biol. Chem. 269(47):29760-4 (1994);			
	Sekiguchi and Shuman, "Vaccinia topoisomerase binds circumferentially to DNA," J. Biol. Chem. 269(50):31731-4 (1994);			
	Sekiguchi et al. "Kinetic anlysis of DNA and RNA strand transfer reactions catalyzed by vaccinia topoisomerase," J. Biol. Chem. 272(25):15721-15728 (1997);			
	Sekiguchi et al. "Mechanism of inhibition of vaccinia DNA topoisomerase by novobiocin and coumermycin," J. Biol. Chem. 271(4):2313-22 (1996);			
	Sekiguchi et al. "Resolution of a Holliday junction by vaccinia topoisomerase requires a spacer DNA segment 3' of the CCCTT/ cleavage sites," Nucleic Acids Res. 28(14):2658-63 (2000);			
	Sekiguchi et al. "Resolution of Holliday junctions by eukaryotic DNA topoisomerase I," Proc. Natl. Acad. Sci. U.S.A. 93(2):785-9 (1996);			
	Shatkin, "Capping of eukaryotic mRNAs," Cell 9(4):645-653 (1976);			
	Shuman and Moss, "Identification of a vaccinia virus gene encoding a type I DNA topoisomerase," Proc. Natl. Acad. Sci. U.S.A. 84:7478-7482 (1987);			
<b>EXAMINER</b>	<b>DATE CONSIDERED</b>			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.				

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 53661-AA/JPW/AJM/MML	Serial No. 10/666,486
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicants Stewart Shuman et al.	
		Filing Date September 19, 2003	Group
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	Shuman and Prescott, "Specific DNA cleavage and binding of vaccinia virus DNA topoisomerase I," J. Biol. Chem. 265:17826-17836 (1990);		
	Shuman and Turner, "Site-specific interaction of vaccinia virus topoisomerase I with base and sugar moieties in duplex DNA," J. Biol. Chem. 268(25):18943-50 (1993);		
	Shuman et al. "Characterization of vaccinia virus DNA topoisomerase I expressed in Escherichia coli," J. Biol. Chem. 263:16401-16407 (1988);		
	Shuman et al. "Insertional mutagenesis of the vaccinia virus gene encoding a type I DNA topoisomerase: evidence that the gene is essential for virus growth," Virology 170(1):302-6 (1989);		
	Shuman et al. "Intramolecular synapsis of duplex DNA by vaccinia topoisomerase," EMBO J. 16(21):6584-9 (1997);		
	Shuman et al. "Mapping the active-site tyrosine of vaccinia virus DNA topoisomerase I," Proc. Natl. Acad. Sci. U.S.A. 86(24):9793-7 (1989);		
	Shuman, "Analysis of topoisomerase-DNA interactions by electrophoretic mobility shift assay," Methods Mol. Biol. 95:65-74(2001);		
	Shuman, "DNA strand transfer reactions catalyzed by vaccinia topoisomerase I," J. Biol. Chem. 267:8620-8627 (1992);		
	Shuman, "Novel approach to molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase," J. Biol. Chem. 269(51):32678-32684 (1994);		
	Shuman, "Polynucleotide ligase activity of eukaryotic topoisomerase I," Mol. Cell. 1(5):741-8 (1998);		
	Shuman, "Recombination mediated by vaccinia virus DNA topoisomerase I in Escherichia coli is sequence specific," Proc. Natl. Acad. Sci. U.S.A. 88(22):10104-8 (1991);		
	Shuman, "Site-specific DNA cleavage by vaccinia virus DNA topoisomerase I. Role of nucleotide sequence and DNA secondary structure," J. Biol. Chem. 266(3):1796-1803 (1991);		
	Shuman, "Site-specific interaction of vaccinia virus topoisomerase I with duplex DNA. Minimal DNA substrate for strand cleavage in vitro," J. Biol. Chem. 266(17):11372-11379 (1991);		
EXAMINER	DATE CONSIDERED		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.			

<b>Form PTO-1449</b>	<b>U.S. Department of Commerce Patent and Trademark Office</b>		<b>Atty. Docket No.</b> 53661-AA/JPW/AJM/MML	<b>Serial No.</b> 10/666,486		
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		<b>Applicants</b> Stewart Shuman et al.				
		<b>Filing Date</b> September 19, 2003	<b>Group</b>			
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>						
	Shuman, "Two classes of DNA end-joining reactions catalyzed by vaccinia topoisomerase I," J. Biol. Chem. 267:16755-16758 (1992);					
	Shuman, "Vaccinia DNA topoisomerase I promotes illegitimate recombination in Escherichia coli," Proc. Natl. Acad. Sci. U.S.A. 86(10):3489-93 (1989);					
	Shuman, "Vaccinia virus DNA ligase: specificity, fidelity, and inhibition," Biochemistry 34:16138-16147 (1995);					
	Shuman, "Vaccinia virus DNA topoisomerase: a model eukaryotic type IB enzyme," Biochim. Biophys. Acta. 1400(1-3):321-37 (1998);					
	Stivers et al. "Stereochemical outcome and kinetic effects of Rp- and Sp-phosphorothioate substitutions at the cleavage site of vaccinia type I DNA topoisomerase," Biochemistry 39(18):5561-72 (2000);					
	Stivers et al. "Vaccinia DNA topoisomerase I: single-turnover and steady-state kinetic analysis of the DNA strand cleavage and ligation reactions," Biochemistry 33(1):327-39 (1994);					
	Theus, "A simple assay for determining the capping efficiencies of RNA polymerases used for in vitro transcription," Biotechniques 9(5):610-615 (1990);					
	Wang and Shuman, "Deletions at the carboxyl terminus of vaccinia DNA topoisomerase affect DNA binding and enhance distributivity in DNA relaxation," Biochemistry 36(13):3909-16 (1997);					
	Wang et al. "Mutational analysis of 26 residues of vaccinia DNA topoisomerase identifies Ser-204 as important for DNA binding and cleavage," Biochemistry 36(26):7944-50 (1997);					
	Wexler et al. "A procedure to amplify cDNA from dsRNA templates using the Polymerase chain reaction," Methods Mol. Cell. Biol. 2:273-279 (1991);					
	Wittschieben and Shuman, "Mechanism of DNA transesterification by vaccinia topoisomerase: catalytic contributions of essential residues Arg-130, Gly-132, Tyr-136 and Lys-167," Nucleic Acids Res. 25(15):3001-8 (1997);					
	Wittschieben and Shuman, "Mutational analysis of vaccinia DNA topoisomerase defines amino acid residues essential for covalent catalysis," J. Biol. Chem. 269(47):29978-83 (1994);					
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.						

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.